Alchemia Limited
Related News »
Alchemia Limited (ACL) yesterday announced that the independent Data Safety Monitoring Board (DSMB) for the Phase III clinical trial of its lead cancer drug, HA-Irinotecan, in second or third line metastatic colorectal cancer, has approved the continuation ...
May 23, 2012 at 10:29 | Source: 4-traders (press release)
Alchemia Limited, Brisbane, Australia (ASX:ACL), announces an update on the progress of generic fondaparinux following Dr Reddy's Laboratories' Q4 results and conference call on Friday 11th May 2012. Dr Reddy's does not disclose sales of individual ...
May 12, 2012 at 23:57 | Source: 4-traders (press release)